Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04030195 · ClinicalTrials.gov registry record · Phase 1
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
A Phase 1 study, sponsored by Precision BioSciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04030195: Completed Phase 1 study, sponsored by Precision BioSciences.
NCT04030195 is a Phase 1 study that has completed, run by Precision BioSciences. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04030195, a Phase 1 study, has completed, sponsored by Precision BioSciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r CLL/SLL.
Primary Outcome
The maximum tolerated dose (MTD) is the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- GENETIC PBCAR20A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-03-24 |
| Est. Completion | 2021-06-24 |
| Phase | Phase 1 |
What the finished NCT04030195 record still lists
NCT04030195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04030195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04030195 about?
NCT04030195 is a clinical study titled "Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL". This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r CLL/SLL.
What is the current status of trial NCT04030195?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-03-24. Estimated completion is 2021-06-24.
What interventions are being tested in trial NCT04030195?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), PBCAR20A (GENETIC).
Who is sponsoring clinical trial NCT04030195?
This trial is sponsored by Precision BioSciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04030195's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI